File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Natural killer cell lymphoma/leukemia: Pathology and treatment

TitleNatural killer cell lymphoma/leukemia: Pathology and treatment
Authors
Issue Date1997
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1997, v. 15 n. 2, p. 71-79 How to Cite?
AbstractMalignancies arising from cells of putative natural killer (NK) cell origin have increasingly been recognized as distinct clinicopathological entities. These malignancies are marked by tumour cells with NK cell characteristics, including the immunophenotype of CD2+, surface CD3-, cytoplasmic CD3ε+, CD7 ±, and CD56+, and the genotype of germline T cell receptor gene. A consistent association with monoclonal Epstein-Barr virus infection in the tumour cell has been observed. These tumours are now regarded as putative NK cell lymphoma/leukemia. Pathologically, tumour cells show variable cytological appearances, with frequent angiocentricity and angioinvasion, associated with zonal necrosis. Clinically, most cases occur in the nasal area and upper aerodigestive tract. However, occurrence in non- nasal sites such as the skin, gastrointestinal tract and testis is also observed. A particularly aggressive form of NK lymphoma/leukemia presents fulminantly as disseminated disease sometimes with a leukemic phase. All types of NK lymphoma/leukemia have an extremely poor prognosis with a median survival of less than a year. New modalities of treatment, including the use of high dose chemotherapy and stem cell rescue may be needed to improve treatment outcome.
Persistent Identifierhttp://hdl.handle.net/10722/162175
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_US
dc.contributor.authorChan, ACLen_US
dc.contributor.authorLiang, RHSen_US
dc.date.accessioned2012-09-05T05:17:49Z-
dc.date.available2012-09-05T05:17:49Z-
dc.date.issued1997en_US
dc.identifier.citationHematological Oncology, 1997, v. 15 n. 2, p. 71-79en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/162175-
dc.description.abstractMalignancies arising from cells of putative natural killer (NK) cell origin have increasingly been recognized as distinct clinicopathological entities. These malignancies are marked by tumour cells with NK cell characteristics, including the immunophenotype of CD2+, surface CD3-, cytoplasmic CD3ε+, CD7 ±, and CD56+, and the genotype of germline T cell receptor gene. A consistent association with monoclonal Epstein-Barr virus infection in the tumour cell has been observed. These tumours are now regarded as putative NK cell lymphoma/leukemia. Pathologically, tumour cells show variable cytological appearances, with frequent angiocentricity and angioinvasion, associated with zonal necrosis. Clinically, most cases occur in the nasal area and upper aerodigestive tract. However, occurrence in non- nasal sites such as the skin, gastrointestinal tract and testis is also observed. A particularly aggressive form of NK lymphoma/leukemia presents fulminantly as disseminated disease sometimes with a leukemic phase. All types of NK lymphoma/leukemia have an extremely poor prognosis with a median survival of less than a year. New modalities of treatment, including the use of high dose chemotherapy and stem cell rescue may be needed to improve treatment outcome.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.-
dc.subject.meshDna, Viral - Chemistryen_US
dc.subject.meshGranuloma, Lethal Midline - Pathology - Therapyen_US
dc.subject.meshHerpesvirus 4, Human - Geneticsen_US
dc.subject.meshHumansen_US
dc.subject.meshIn Situ Hybridizationen_US
dc.subject.meshKiller Cells, Natural - Pathologyen_US
dc.subject.meshLeukemia, Lymphoid - Pathology - Therapyen_US
dc.subject.meshLymphoma - Pathology - Therapyen_US
dc.subject.meshNose Neoplasms - Pathology - Therapyen_US
dc.titleNatural killer cell lymphoma/leukemia: Pathology and treatmenten_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1099-1069(199705)15:2<71::AID-HON601>3.0.CO;2-Uen_US
dc.identifier.pmid9375032-
dc.identifier.scopuseid_2-s2.0-0030733790en_US
dc.identifier.hkuros28761-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030733790&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume15en_US
dc.identifier.issue2en_US
dc.identifier.spage71en_US
dc.identifier.epage79en_US
dc.identifier.isiWOS:A1997YE59700003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridChan, ACL=16047349300en_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats